Pharma News

Reduced cell density in certain parts of the hippocampus - a brain region that processes and stores memories - may be linked to deficits in short- and long-term memory in people with epilepsy, particularly those with seizures that affect the temporal lobe, new research has found.

Older adults with chronic lymphocytic leukemia, a type of slow-growing blood cancer, may have a better alternative to toxic chemotherapy as their first treatment, results of a phase three clinical trial show.

With diabetes affecting a large section of India's population, the chronic health condition can adversely affect the country's economic growth, experts have warned.

Scientists at University College London (UCL) have found the recipe for painlessness in a study that used genetically modified mice to show a channel responsible for allowing pain signals to pass along nerve cell membranes is vital to feel agony.

Sun Pharmaceutical Industries Ltd. has received final approval from US FDA for its Abbreviated New Drug Application (ANDA) for generic version of Gleevec®, Imatinib Mesylate tablets 100mg and 400mg. Gleevec® is the registered trademark of Novartis Pharmaceuticals Corporation.

Cipla Ltd, a global pharmaceutical company announced that it has launched a novel “5 in 1” anti-ageing skin care product Cutisera developed by Stempeutics. Cutisera has been developed using bio-active factors derived from human adult stem cells to enhance the rejuvenation of ageing skin.

Advaxis, Inc., a clinical-stage biotechnology company developing cancer immunotherapies, announced that the European Medicines Agency (EMA) granted Orphan Drug Designation for ADXS-HER2 for the treatment of osteosarcoma.

Biotronik, the world’s leading manufacturer of MR conditional cardiac devices, has announced that its Eluna 8 pacemaker is now available in Japan. The pacemaker is approved for 1.5 tesla (T) full-body MRI scans, and ultra-high strength 3.0 T MRI scans with an exclusion zone.

AbbVie, a global biopharmaceutical company, announced its New Drug Application (NDA) has been accepted by the U.S. Food and Drug Administration (FDA) for a once-daily, fixed-dose formulation of the components of VIEKIRA PAK® (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets). VIEKIRA PAK is an all-oral, interferon-free treatment approved with or without ribavirin (RBV) in the United States for patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, including those with compensated cirrhosis. VIEKIRA PAK is not for people with decompensated cirrhosis.

Chinese doctors have cured a patient of leukemia using gene therapy, a hospital in Chongqing announce. Zhang Fang, a middle-aged woman, has been cured of leukemia after she was treated with CAR T therapy, Xinhua reported.

[adsense:336x280:8701650588]